ACE Inhibition and Novel Cardiovascular Risk Factors (TRAIN)

Long Name: ACE Inhibition and Novel Cardiovascular Risk Factors (TRAIN)

TRAIN is  a double-blind cross-over randomized placebo controlled trial in 294 persons with high cardiovascular risk to assess the effects of 6 month treatment with fosinopril and 6 months with placebo on several markers of fibrinolysis, inflammation, endothelial function and extracellular matrix remodeling. The effects of several genetic polymorphisms were studied on these biomarkers, and test the interaction of the gene polymorphisms with the effects of fosinopril. The assessment of these biological mechanisms will have clinical relevance for identifying the patients who may benefit the most from ACE inhibition. All follow up visits have been completed and data analysis is under way.
Last Updated: 12-09-2015
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.